Vaccine and biotechnology names are leading a sharp sector rally, and a small protein-vaccine developer is posting the ...

<?xml encoding="utf-8" ?> A nationwide initiative to accelerate personalized cancer vaccine development is drawing fresh ...

Moderna stock popped 9% on Friday after the New York Times reported new details about an effort to speed up cancer vaccine development. Investors saw the mRNA biotech company, in particular, as a ...

No plague case has been confirmed, and no government orders have been announced, but outbreak-linked stocks jumped anyway.

Healthcare stocks rose Friday afternoon, with the NYSE Healthcare Index up 1.2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.6%. The iShares Biotechnolog ...

U.S. stocks closed higher on Friday, led by a tech-sector rebound, with the Dow surging more than 400 points and all three major indexes ...

Novavax jumped 20% and Moderna rose 7% after a Russian lab worker died from suspected plague exposure. Vaccine and biodefense ...

Moderna has nearly tripled in a single month without a single new trial result or analyst upgrade to explain Thursday's continued surge, and the one clue hiding in a quiet peer stock reveals exactly ...

Gilead’s $7.8 billion buyout of Arcellx closed in April. The more durable return may be the operators that deal released into ...

Vaccine stocks including Novavax and Moderna rallied after a lab technician died following suspected plague exposure at a ...

Sanofi CEO Belén Garijo described the firm’s more than two-decade partnership with Regeneron as “one of the most productive ...

Novavax surged 20% and Moderna gained 7% after a Russian lab worker died from suspected plague exposure. Biodefense and ...